DDInter1544 DDInter1281
Prucalopride is a dihydrobenzofurancarboxamide derivative from the benzofurane family that selectively stimulates 5-HT4 receptors and thus, it presents enterokinetic properties. The high selectivity of prucalopride allowed further development as it prevented the cardiac adverse reactions observed due to non-target effects of precedent therapies. Prucalopride was developed by Shire Development LLC and approved for use in Europe in 2009, in Canada on December 7, 2011 and by the FDA on December 17, 2018.
Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer.
Neratinib {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Lapatinib
Neratinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Binimetinib
Neratinib {u} may lead to a major life threatening interaction when taken with {v} Colchicine
Neratinib {u} may lead to a major life threatening interaction when taken with {v} Fedratinib
Neratinib may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib
Neratinib may cause a moderate interaction that could exacerbate diseases when taken with Binimetinib
Neratinib may lead to a major life threatening interaction when taken with Colchicine
Neratinib may lead to a major life threatening interaction when taken with Fedratinib